Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569311 | 0.98 | L3MBTL1 (0.41) | L3MBTL1LMNAALDH1A1KMT2AHPGD | |
| SCHEMBL314403 | 0.84 | L3MBTL1 (0.43) | L3MBTL1LMNAALDH1A1KMT2AHPGD | |
| SCHEMBL6019680 | 0.82 | SMN1; SMN2 (0.46) | L3MBTL1LMNAALDH1A1KMT2AHPGD | |
| SCHEMBL696377 | 0.82 | L3MBTL1 (0.43) | L3MBTL1LMNAALDH1A1KMT2AHPGD | |
| SCHEMBL3116769 | 0.81 | TDP1 (0.45) | L3MBTL1LMNAALDH1A1KMT2AEPHX1 | |
| SCHEMBL27753788 | 0.81 | L3MBTL1 (0.41) | L3MBTL1LMNAALDH1A1KMT2AHPGD | |
| SCHEMBL11096063 | 0.81 | L3MBTL1 (0.41) | L3MBTL1LMNAALDH1A1KMT2AHPGD | |
| SCHEMBL1438977 | 0.78 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL163813 | 0.78 | SMN1; SMN2 (0.47) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30559928 | 0.78 | L3MBTL1 (0.38) | L3MBTL1LMNAALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | disclosed |
| EP-2097079-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | Hunter-Fleming Limited (GB) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065408-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
| EP-1848426-A2 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | Hunter-Fleming Limited (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082409-A2 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2006-08-10 | — | — | WO | disclosed |
| EP-1471901-A1 | SPERMIDINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHAMPTON (GB) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066037-A1 | SPERMIDINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHAMPTON (GB) | 2003-08-14 | — | — | WO | disclosed |
| EP-1040096-A1 | NEUROPROTECTIVE AGENTS | THE UNIVERSITY OF SOUTHAMPTON (GB) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999031049-A1 | NEUROPROTECTIVE AGENTS | UNIVERSITY OF SOUTHAMPTON (GB) | 1999-06-24 | — | — | WO | disclosed |